Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04163328
Other study ID # 000526521
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date September 16, 2022
Est. completion date December 31, 2024

Study information

Verified date June 2024
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

HydroEye® is a dietary supplement that contains both EPA and DHA, as well as GLA and ALA in the form of black currant seed oil. It also has vitamins A, E, C, B6, and magnesium, many of which are involved in fatty acid metabolism. In 2013, Sheppard et al. tested HydroEye® in dry eye patients who were not contact lens wearers and found that symptoms and corneal smoothness improved in response to HydroEye® supplementation. To date, HydroEye® has not been assessed in patients with contact lens discomfort; therefore, the purpose of this clinical trial is to determine the efficacy of HydroEye® as a treatment for contact lens discomfort.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 42
Est. completion date December 31, 2024
Est. primary completion date August 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years 2. Provide informed consent and authorization to disclose protected health information 3. Willing to follow study protocol 4. Habitual, contact lens-corrected visual acuity of at least 20/30 in each eye 5. Wear soft contact lenses as daily wear for at least 6 hours per day and at least 5 days per week for the past 30 days 6. Have at least a 2-hour difference between overall wear time and comfortable wear time of contact lenses 7. Have symptoms consistent with Contact Lens Dry Eye based on CLDEQ-8 (score = 12) 8. Increased severity of dry eye symptoms with contact lens wear by at least 25% as determined by patient self-report 9. Clinical assessment that contact lens material, fit, prescription, and care system are not reasons for contact lens discomfort 10. Demonstrate at least 80% compliance in completion of daily electronic diary (submitted through Qualtrics Research Suite) between V1 and V2 11. Willing to discontinue use of any current dry eye treatment (including use of commercial hygiene masks, and except for artificial tears) for 4 weeks before randomization and during the course of the 6-month study. Exclusion Criteria: 1. Meibomian gland dropout =75% in either eyelid 2. Any changes to the contact lens material, fit, prescription, or care system in the 30 days preceding enrollment or anticipates needing to make changes during the course of the study 3. Any systemic disease known to be associated with dry eye 4. Any significant ocular surface abnormality that could be associated with ocular surface discomfort, such as ectropion, entropion, trichiasis, infection, severe allergic conjunctivitis, severe eyelid inflammation, etc. 5. Any overnight wear of contact lenses or use of daily disposable contact lenses 6. Any previous corneal surgery, including all types of corneorefractive surgery 7. Have temporary and/or permanent punctal plugs inserted 8. Use of supplemental fish oil, or seed oils from borage, evening primrose, sea buckthorn, flaxseed, or black currant within the last 60 days 9. Routine, usual dietary intake of more than 8 oz. of cold-water fatty fish (tuna, salmon, mackerel, sea bass, sardines or herring) per week). 10. Use of anticoagulant therapy or regular, daily use of aspirin, NSAIDs, or steroid medications within the past 30 days, or a history of easy bruising 11. Allergy or intolerance to fish or any ingredients contained in the active or placebo formulas [See appendix or ingredient list] 12. Participation in a clinical trial in the past 30 days 13. Current pregnancy or breast feeding as indicated by self-report

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HydroEye®
This is an omega-3 fatty acids supplement.

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Contact Lens Dry Eye Questionnaire (CLDEQ-4) The CLDEQ-4 is a contact lens specific symptoms survey, we are using the Rasch validated version; range = 0-18 with 18 being most symptomatic. Mean change at 6 months.
Secondary Tear LTB4 Levels LTB4 values will be tested with a biochemical assay to estimate eye surface inflammation. Mean change at 6 months.
Secondary Standardized Patient Evaluation of Eye Dryness (SPEED) Questionnaire The SPEED is a dry eye specific symptoms survey, we are using the Rasch validated version; range = 0-28 with 28 being most symptomatic. Mean change at 6 months.
Secondary Neuropathic Pain Symptom Inventory (NPSI) Questionnaire NPSI is a pain specific symptoms survey; range = 0-100 with 100 being most symptomatic. Mean change at 6 months.
Secondary Tear Breakup Time This is a measure of tear stability with higher values being better (seconds). Mean change at 6 months.
Secondary Schirmer I Test This is a measure of tear volume with higher values being better (0 mm - 35 mm). Mean change at 6 months.
Secondary Corneal Staining This is a measure of eye irritation with higher values being worse (NEI scale with range of 0 to 15). Mean change at 6 months.
Secondary Conjunctival Staining This is a measure of eye irritation with higher values being worse (NEI scale with range of 0 to 18). Mean change at 6 months.
See also
  Status Clinical Trial Phase
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Recruiting NCT04527887 - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) Phase 4
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A